$ACAD
ACADIA PHARMACEUTICALS INC

2021 Q1 Form 10-Q Financial Statement

#000156459021024268 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $106.6M $90.07M
YoY Change 18.3% 43.06%
Cost Of Revenue $2.185M $5.000M
YoY Change -56.3% 69.49%
Gross Profit $104.4M $87.27M
YoY Change 19.59% 45.43%
Gross Profit Margin 97.95% 96.89%
Selling, General & Admin $111.7M $102.0M
YoY Change 9.5% 9.54%
% of Gross Profit 106.99% 116.85%
Research & Development $56.97M $72.64M
YoY Change -21.56% 37.25%
% of Gross Profit 54.59% 83.23%
Depreciation & Amortization $525.0K $294.0K
YoY Change 78.57% -29.16%
% of Gross Profit 0.5% 0.34%
Operating Expenses $168.6M $174.6M
YoY Change -3.42% 19.58%
Operating Profit -$66.77M -$89.52M
YoY Change -25.41% 2.15%
Interest Expense $200.0K $3.000M
YoY Change -93.33% 2.25%
% of Operating Profit
Other Income/Expense, Net -$145.0K $1.497M
YoY Change -109.69% 553.71%
Pretax Income -$66.43M -$88.00M
YoY Change -24.51% 3.62%
Income Tax $21.00K $0.00
% Of Pretax Income
Net Earnings -$66.45M -$88.02M
YoY Change -24.51% 3.19%
Net Earnings / Revenue -62.36% -97.73%
Basic Earnings Per Share -$0.42
Diluted Earnings Per Share -$415.0K -$566.3K
COMMON SHARES
Basic Shares Outstanding 155.3M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $577.8M $651.4M
YoY Change -11.3% 57.22%
Cash & Equivalents $304.5M $173.1M
Short-Term Investments $273.3M $478.3M
Other Short-Term Assets $28.50M $22.10M
YoY Change 28.96% -6.75%
Inventory $10.31M $6.318M
Prepaid Expenses
Receivables $56.80M $41.60M
Other Receivables $600.0K $3.000M
Total Short-Term Assets $674.0M $724.4M
YoY Change -6.96% 52.06%
LONG-TERM ASSETS
Property, Plant & Equipment $72.90M $13.70M
YoY Change 432.12% 266.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.600M $7.100M
YoY Change 7.04% 353.67%
Total Long-Term Assets $81.20M $23.10M
YoY Change 251.52% -6.47%
TOTAL ASSETS
Total Short-Term Assets $674.0M $724.4M
Total Long-Term Assets $81.20M $23.10M
Total Assets $755.2M $747.5M
YoY Change 1.03% 49.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.800M $6.600M
YoY Change 33.33% 101.53%
Accrued Expenses $100.5M $93.12M
YoY Change 7.95% 29.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $109.4M $99.70M
YoY Change 9.73% 32.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $64.20M $9.300M
YoY Change 590.32% 818.97%
Total Long-Term Liabilities $64.20M $9.300M
YoY Change 590.32% 818.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $109.4M $99.70M
Total Long-Term Liabilities $64.20M $9.300M
Total Liabilities $173.6M $109.1M
YoY Change 59.12% 31.84%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $581.6M $638.4M
YoY Change
Total Liabilities & Shareholders Equity $755.2M $747.5M
YoY Change 1.03% 49.17%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$66.45M -$88.02M
YoY Change -24.51% 3.19%
Depreciation, Depletion And Amortization $525.0K $294.0K
YoY Change 78.57% -29.16%
Cash From Operating Activities -$60.15M -$49.00M
YoY Change 22.75% -23.64%
INVESTING ACTIVITIES
Capital Expenditures $1.076M -$930.0K
YoY Change -215.7% -213.14%
Acquisitions
YoY Change
Other Investing Activities $31.95M $30.54M
YoY Change 4.62% 29.52%
Cash From Investing Activities $30.88M $29.61M
YoY Change 4.29% 30.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.726M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.726M 3.754M
YoY Change 105.81% -10.11%
NET CHANGE
Cash From Operating Activities -60.15M -49.00M
Cash From Investing Activities 30.88M 29.61M
Cash From Financing Activities 7.726M 3.754M
Net Change In Cash -21.54M -15.64M
YoY Change 37.75% -58.01%
FREE CASH FLOW
Cash From Operating Activities -$60.15M -$49.00M
Capital Expenditures $1.076M -$930.0K
Free Cash Flow -$61.23M -$48.07M
YoY Change 27.36% -26.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
106554000
CY2021Q1 acad License Fees And Royalty Expense
LicenseFeesAndRoyaltyExpense
2507000
CY2020Q1 acad License Fees And Royalty Expense
LicenseFeesAndRoyaltyExpense
2175000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56973000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72636000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
111661000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
101973000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
173326000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
179583000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
145000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1497000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-66448000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-88023000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1226000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-66448000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
13184000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-689000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
370000
CY2021Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
145000
CY2020Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-1497000
CY2020Q1 us-gaap Depreciation
Depreciation
294000
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2821000
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3520000
CY2021Q1 acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-1589000
CY2020Q1 acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-1187000
CY2021Q1 acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1052000
CY2020Q1 acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-360000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60149000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49002000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1076000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30877000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29608000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7726000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21541000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15638000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331798000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7726000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3754000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194467000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
627009000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
699135000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1228000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
581606000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
638382000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4787000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331798000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
310257000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194467000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
178829000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
326028000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
304487000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
189680000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173059000
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7731000
CY2016Q2 acad Regulatory Milestone Payment
RegulatoryMilestonePayment
8000000.0
CY2016Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8000000.0
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
700000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20297000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21064000
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
947000
CY2021Q1 acad Equity Securities Fv Ni Unrealized Gains
EquitySecuritiesFvNiUnrealizedGains
34000
CY2021Q1 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
10000
CY2021Q1 acad Equity Securities Fv Ni Unrealized Losses
EquitySecuritiesFvNiUnrealizedLosses
10000
CY2021Q1 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
273281000
CY2021Q1 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
273281000
CY2020Q4 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
305899000
CY2021Q1 us-gaap Inventory Net
InventoryNet
10311000
CY2020Q4 us-gaap Inventory Net
InventoryNet
9682000
CY2021Q1 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
23886000
CY2020Q4 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
14115000
CY2021Q1 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
22177000
CY2020Q4 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
28380000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21767000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25811000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6082000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5087000
CY2021Q1 acad Accrued Branded Prescription Drug Fees Current
AccruedBrandedPrescriptionDrugFeesCurrent
5203000
CY2020Q4 acad Accrued Branded Prescription Drug Fees Current
AccruedBrandedPrescriptionDrugFeesCurrent
1845000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3039000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3267000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
100524000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
97474000
CY2021Q1 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
273257000
CY2021Q1 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
273257000
CY2021Q1 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
34000
CY2020Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
74000
CY2020Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
43000
CY2020Q4 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
305930000
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
15
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
24
CY2021Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
97422000
CY2021Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
10000
CY2021Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
97422000
CY2021Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
10000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
169353000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
43000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
169353000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
43000
CY2021Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
576951000
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
632576000
CY2021Q1 acad Obligation Expiration Year
ObligationExpirationYear
2021
CY2021Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 0.8 years to 10.2 years, some of which include options to extend for up to two five-year terms.
CY2021Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
some of which include options to extend for up to two five-year terms.
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2378000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1487000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1014000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1291000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17417000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
276000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6082000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5087000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
60581000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44460000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
66663000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
49547000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4071000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8739000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8506000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8275000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8355000
CY2021Q1 acad Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
44276000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
82222000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15559000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
66663000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y7M6D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.044
CY2020Q3 acad Capitalization Of Right Of Use Asset
CapitalizationOfRightOfUseAsset
40300000
CY2020Q3 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
40300000
CY2021Q1 acad Capitalization Of Right Of Use Asset
CapitalizationOfRightOfUseAsset
19200000
CY2021Q1 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
19200000

Files In Submission

Name View Source Status
0001564590-21-024268-index-headers.html Edgar Link pending
0001564590-21-024268-index.html Edgar Link pending
0001564590-21-024268.txt Edgar Link pending
0001564590-21-024268-xbrl.zip Edgar Link pending
acad-10q_20210331.htm Edgar Link pending
acad-10q_20210331_htm.xml Edgar Link completed
acad-20210331.xsd Edgar Link pending
acad-20210331_cal.xml Edgar Link unprocessable
acad-20210331_def.xml Edgar Link unprocessable
acad-20210331_lab.xml Edgar Link unprocessable
acad-20210331_pre.xml Edgar Link unprocessable
acad-ex101_299.htm Edgar Link pending
acad-ex102_302.htm Edgar Link pending
acad-ex103_300.htm Edgar Link pending
acad-ex104_301.htm Edgar Link pending
acad-ex311_6.htm Edgar Link pending
acad-ex312_10.htm Edgar Link pending
acad-ex321_9.htm Edgar Link pending
acad-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending